Development of proprietary medicines
We look for new medicines in oncology, neuropsychiatry, diabetology and virology
The development of innovative drugs at Adamed is focused on four therapeutic areas: diabetology, oncology, neuropsychiatry and virology. We have the capacity to vigorously execute highly complex projects, such as the development of new molecules, thanks to our multidisciplinary team of experts working in modern laboratories with advanced technological facilities.
Our laboratories enable agile application of technologies which are needed to select and test drug candidates and transfer them to the clinical development stage. We have the know-how to: a) produce small-molecule compounds using chemical synthesis, as well as biological molecules by employing chemical and biotechnological methods; b) analyze the same by chemical, biochemical and biophysical methods; c) study the functionality and efficiency of these molecules by cell or tissue biology methods; and d) determine the potential of these molecules to progress to further stages of development by establishing their safety profile in toxicological studies, as well as pharmacokinetic and pharmacodynamic characteristics in in vivo methods. In our research projects we also use advanced mathematical tools both for data analysis and for in silico modelling during the design phase and when optimizing the molecules which exhibit a therapeutic potential.
Currently, we are implementing projects focusing on six research programmes through which we have selected three molecules which are drug candidates at the stage of transfer to clinical trials. The first one is a licenced-out small molecule developed in indication mental disorders. The second one is a selective MDM2 and p53 protein inhibitor which exhibits cancer-fighting activity in sarcomas, lymphomas, and leukemias. The third molecule is a recombinant fusion protein with pro-apoptotic and anti-angiogenic activity. It is a drug candidate for solid tumors of the gastrointestinal tract.
In the other three research programmes we are in the process of selecting and optimizing molecules. In the first programme, these are anti-cancer molecules and in the other programme, molecules which are intended to be used for treatment of civilization diseases, such as type 2 diabetes and obesity, in the third, fast acting molecules in treatment of depression.
Project is co-financed by Medical Research Agency, program: Development of targeted and personalized medicine based on targeted cell therapies and protein products Project value: 35,3B PLN.
The value of the project is PLN 34 749 466.78, of which PLN 18 170 000 are funds from the National Center for Research and Development granted under the Fast Track Program for Mazovia for the project "Clinical development of an innovative anti-cancer compound based on p53 protein activation mechanism”, " "MAZOWSZE / 0012/19-00".
The necessity of finding new oncological therapies and the development of drug resistance in some types of cancer drive the search for new anticancer therapies. As part of this search Adamed initiated 6 early discovery projects in the field of oncology, the most promising of which will be selected for full preclinical development.
The value of the project is over 30 million PLN, which includes more than 19 million PLN of funds from the National Centre for Research and Development granted under the Smart Growth Operational Programme.
The value of the project is over 87 million PLN , of which almost 60 million are funds from the state budget. The project is co-financed by ABM.
Innovation Department Labs & Teams
The Lab possesses infrastructure and software for the modelling, visualisation, and comparative analysis of spatial structures which are molecular binding sites for newly developed medicines, effector molecules, and their mutual interactions. The team also has expertise in high-throughput compound analysis and protein sequencing. The Lab also develops Adamed’s own research algorithms and database software for the collection, analysis, and processing of results obtained through experiments.
The Biotechnology Lab is responsible for developing protein production processes as part of Adamed’s innovative research programmes. The Lab’s tasks include optimisation of the following protein manufacturing stages: designing DNA constructs coding the target molecules, selection of bacterial strains and expression vectors, establishing the optimal conditions for expression, and scaling the manufacturing process.
Content: The main activities of the Proteomics Lab include the design and implementation of purification methods for recombinant proteins with therapeutic potential, analytics of proteins and bioconjugates, and providing their exact characteristics. An important part of the Lab’s work is participation in studies of molecular mechanisms of action and molecule pharmacology to prepare the molecules for advanced stages of the development process as drug candidates.
Content: Eukaryotic cell cultures are routinely used in biotechnological and toxicological protocols. Cells cultivated in appropriate conditions can be used for screening newly created molecules, thereby significantly reducing the number of animal tests. At the early stages of the drug development process, properly planned experiments using cell lines enable investigators to answer many questions about the mechanism of action, initial toxicological activity, or interactions with other substances.
The Laboratory Animals Team is responsible for conducting research studies to acquire the knowledge necessary for the development of drug candidates. The Team follows national and European guidelines and is committed to maintaining high ethical, hygienic, and methodological standards in the rodent vivarium. Ensuring the welfare of laboratory animals based on the 3R principle and close collaboration with the Research Department, the Preclinical Development Team, and external expert organisations allow the Team to accurately conduct studies in order to ensure highly reliable results.
The Preclinical Development Team coordinates the company’s activities in the area of preclinical studies of selected drug candidates. With its vast skills and experience, the Team can efficiently assess if molecules are ready for phase 1 clinical trials (known as first-in-human, FIH) and provide significant support for finished value-added dosage forms, allowing Adamed to obtain regulatory approval for bringing new medicines to the Polish and international markets.
Content: The CNS Team is responsible for all research activities carried out by the Innovation Department in the area of central nervous system disorders. The Team’s tasks include the selection of clinical indications and biological targets, designing new chemical molecules with therapeutic potential, and providing broad in vitro and in vivo pharmacological characteristics.
Institute of Biochemistry and Biophysics
Polish Academy of Sciences in Warsaw
Institute of Physical Chemistry
Polish Academy of Sciences in Warsaw
Institute of Immunology and Experimental Therapy
Polish Academy of Sciences in Wroclaw
Wroclaw Research Centre EiT+
of Molecular and Cell Biology
Institute of Industrial Organic Chemistry,
Branch Office in Pszczyna
Pharmaceutical Research Institute
Faculty of Pharmacy,
Jagiellonian University Collegium Medicum
The John Paul II Catholic University in Lublin
Institute of Pharmacology,
Polish Academy of Sciences in Krakow
Institute of Psychiatry and Neurology
Institute of Mother and Child
Haematology and Transfusion
The Maria Skłodowska-Curie
Institute Oncology Centre
Medical Centre of Postgraduate Education
Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University